Hepatic Arterial Infusion Pump Chemotherapy Improves Survival Outcomes for Intrahepatic Cholangiocarcinoma
According to results from a phase 2 trial, combining hepatic arterial infusion pump (HAIP) chemotherapy with systemic therapy was associated with improved 3-year overall survival (OS) among patients with advanced intrahepatic cholangiocarcinoma, compared with systemic chemotherapy alone.
These results were presented by Bas Groot Koerkamp, MD, Amsterdam UMC, Amsterdam, Netherlands, at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium on Friday, January 19, 2024, in Francisco, California.
In this single-arm, multicenter study, 49 patients with advanced intrahepatic cholangiocarcinoma were enrolled and underwent treatment. Of the 50 total, 38 patients were treated with both HAIP and systemic chemotherapy, 11 patients were treated with HAIP chemotherapy alone as they had previously received systemic chemotherapy prior to enrollment. HAIP was administered with floxuridine over 6 cycles, concurrently with 8 cycles of systemic gemcitabine-cisplatin chemotherapy when patients had not received prior systemic therapy. The primary end point of this study was overall survival (OS). Secondary end points included progression-free survival (PFS), and objective response.
The median follow-up was 16.4 months. Median OS was 22.1 months, with an 1-year OS rate of 80.0% and a 3-year OS rate of 28.6%. The median PFS was 0.0 months. The objective response rate was 54%, with 43 patients achieving disease control at 6 months. Following HAIP chemotherapy, 4 patients underwent resection, 2 of whom had a complete pathologic response.
According to Dr Groot Koerkamp and coauthors, “Combined HAIP with systemic chemotherapy for patients with advanced [intrahepatic cholangiocarcinoma] was associated with a favorable 3-year OS of 28.6% compared with 2.8% after systemic chemotherapy alone in the ABC trials.”
Source:
Franssen S, Rousian M, Nooijen LE, et al. Hepatic arterial infusion pump chemotherapy in patients with advanced intrahepatic cholangiocarcinoma confined to the liver: A multicenter phase II trial. Presented at 2024 ASCO Gastrointestinal Cancer Symposium; January 18-20, 2024; San Francisco, California. Abstract 433
